U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C29H38FN2O2
Molecular Weight 465.6226
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 1

SHOW SMILES / InChI
Structure of AZD-9164

SMILES

C[C@@](N1CCCCC1)(C(=O)O[C@H]2C[N+]4(CCC3=CC=C(F)C=C3)CCC2CC4)C5=CC=CC=C5

InChI

InChIKey=FNYFFCOCVNTJCD-NNMXADRKSA-N
InChI=1S/C29H38FN2O2/c1-29(25-8-4-2-5-9-25,31-17-6-3-7-18-31)28(33)34-27-22-32(20-15-24(27)16-21-32)19-14-23-10-12-26(30)13-11-23/h2,4-5,8-13,24,27H,3,6-7,14-22H2,1H3/q+1/t24?,27-,29-,32?/m0/s1

HIDE SMILES / InChI
Molecular Formula C29H38FN2O2
Molecular Weight 465.6226
Charge 1
Count
Stereochemistry EPIMERIC
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

AZD9164 was invented by AstraZeneca as a muscarinic M(3) receptor antagonist for evaluation of the potential as a treatment for chronic obstructive pulmonary disease. However, in 2010 studies were discontinued.

Originator

Approval Year

Unknown
139594
PubMed

PubMed

TitleDatePubMed
The discovery of AZD9164, a novel muscarinic M3 antagonist.
2011 Dec 15
Overcoming non-specific adsorption issues for AZD9164 in human urine samples: consideration of bioanalytical and metabolite identification procedures.
2012 Apr 15
Long acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs.
2017 Feb

Sample Use Guides

In Vivo Use Guide
Solution for inhalation through nebulization, single dose. AZD9164 solution for inhalation through nebulisation 100 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation
Route of Administration: Other
Substance Class Chemical
Created
by admin
on Sat Dec 16 10:14:06 GMT 2023
Edited
by admin
on Sat Dec 16 10:14:06 GMT 2023
Record UNII
977LWC4O5D
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AZD-9164
Common Name English
AZD9164
Code English
AZD 9164 [WHO-DD]
Common Name English
J3.232.015E
Code English
1-AZONIABICYCLO(2.2.2)OCTANE, 1-(2-(4-FLUOROPHENYL)ETHYL)-3-((2S)-1-OXO-2-PHENYL-2-(1-PIPERIDINYL)PROPOXY)-, (3R)-
Systematic Name English
1-(4-FLUOROPHENETHYL)-3.BETA.-((S)-2-PHENYL-2-(1-PIPERIDINYL)PROPIONYLOXY)QUINUCLIDINIUM
Systematic Name English
Code System Code Type Description
CAS
1034978-04-5
Created by admin on Sat Dec 16 10:14:06 GMT 2023 , Edited by admin on Sat Dec 16 10:14:06 GMT 2023
PRIMARY
PUBCHEM
44517831
Created by admin on Sat Dec 16 10:14:06 GMT 2023 , Edited by admin on Sat Dec 16 10:14:06 GMT 2023
PRIMARY
FDA UNII
977LWC4O5D
Created by admin on Sat Dec 16 10:14:06 GMT 2023 , Edited by admin on Sat Dec 16 10:14:06 GMT 2023
PRIMARY
DRUG BANK
DB12115
Created by admin on Sat Dec 16 10:14:06 GMT 2023 , Edited by admin on Sat Dec 16 10:14:06 GMT 2023
PRIMARY
Related Record Type Details
Structure of AZD-9164 BROMIDE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of AZD-9164
ACTIVE MOIETY
Originator: AstraZeneca; Mechanism of Action: Muscarinic receptor antagonist; Highest Development Phase: Discontinued for Chronic obstructive pulmonary disease; Most Recent Events: 29 Jun 2010 Discontinued - Phase-II for Chronic obstructive pulmonary disease in Sweden (Inhalation), 28 Jun 2010 AtraZeneca terminates phase I trial (NCT01016951) in Chronic obstructive pulmonary disease in Sweden as one of the stopping criterion was met, 30 Jun 2009 Phase-II clinical trials in Chronic obstructive pulmonary disease in Sweden (Inhalation)
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966